Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Amifostine and High-Dose Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Chronic Myelogenous Leukemia
This study is ongoing, but not recruiting participants.
Study NCT00003407 Information provided by National Cancer Institute (NCI)
First Received: November 1, 1999 Last Updated: May 9, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Drug/Agent Toxicity by Tissue/Organ
Leukemia
Myelodysplastic Syndromes
Neutropenia
Additional conditions recognized in this trial
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Preleukemia
Syndrome
More general conditions related to this trial
Agranulocytosis
Bone Marrow Diseases
Disease
Hematologic Diseases
Leukocyte Disorders
Leukopenia
Myeloproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Pathologic Processes
Precancerous Conditions
Interventions listed in this trial
amifostine trihydrate
cytarabine
mitoxantrone hydrochloride
Additional drug interventions recognized in this trial
Amifostine
Mitoxantrone
More general drug interventions related to this trial
Analgesics
Anti-Infective Agents
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antiviral Agents
Central Nervous System Agents
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Protective Agents
Radiation-Protective Agents
Sensory System Agents
Therapeutic Uses
Sponsors listed in this trial
Rush University Medical Center
National Cancer Institute (NCI)
Back to top of Main Content
